Routine prophylactic sentinel lymph node biopsy is not indicated in women undergoing prophylactic mastectomy

Journal of Surgical Oncology

Volumn 105, Issue 7, 2012, Pages 650-654

  Czyszczon, Irene Alina ^a   Roland, Lane ^b   Sahoo, Sunati ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

breast carcinoma; mastectomy; prophylactic; sentinel lymph node biopsy

Indexed keywords

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST; BREAST FIBROADENOMA; CANCER INCIDENCE; CANCER PREVENTION; CANCER STAGING; CARCINOMA IN SITU; FEMALE; HUMAN; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCULT CANCER; PAPILLOMA; PRIORITY JOURNAL; PROPHYLACTIC MASTECTOMY; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MASTECTOMY; MIDDLE AGED; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY;

EID: 84859903070     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23018     Document Type: Article

References (23)

1. Scott CI, Iorgulescu DG, Thorne HJ, et al.: Clinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy. Clin Genet 2003; 64: 111-121. (Pubitemid 36944103)
2. Ford D, Easton DF, Stratton M, et al.: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-689. (Pubitemid 28164626)
3. Struewing JP, Hartge P, Wacholder S, et al.: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 1401-1408. (Pubitemid 27208598)
4. Bilimoria MM, Morrow M,: The woman at increased risk for breast cancer: Evaluation and management strategies. CA Cancer J Clin 1995; 45: 263-278.
5. Boughey JC, Khakpour N, Meric-Bernstam F, et al.: Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer 2006; 107: 1440-1447. (Pubitemid 44546902)
6. Dupont EL, Kuhn MA, McCann C, et al.: The role of sentinel lymph node biopsy in women undergoing prophylactic mastectomy. Am J Surg 2000; 180: 274-277.
7. McLaughlin SA, Stempel M, Morris EA, et al.: Can magnetic resonance imaging be used to select patients for sentinel lymph node biopsy in prophylactic mastectomy? Cancer 2008; 112: 1214-1221. (Pubitemid 351429736)
8. Laronga C, Lee MC, McGuire KP, et al.: Indications for sentinel lymph node biopsy in the setting of prophylactic mastectomy. J Am Coll Surg 2009; 209: 746-752 (quiz 800-741).
9. Leidenius M, Leivonen M, Vironen J, et al.: The consequences of long-time arm morbidity in node-negative breast cancer patients with sentinel node biopsy or axillary clearance. J Surg Oncol 2005; 92: 23-31. (Pubitemid 41416425)
10. Tuttle TM, Habermann EB, Grund EH, et al.: Increasing use of contralateral prophylactic mastectomy for breast cancer patients: A trend toward more aggressive surgical treatment. J Clin Oncol 2007; 25: 5203-5209. (Pubitemid 350232251)
11. Rebbeck TR, Friebel T, Lynch HT, et al.: Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J Clin Oncol 2004; 22: 1055-1062. (Pubitemid 41095038)
12. Hartmann LC, Sellers TA, Schaid DJ, et al.: Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001; 93: 1633-1637. (Pubitemid 33094870)
13. Meijers-Heijboer H, van Geel B, van Putten WL, et al.: Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 159-164. (Pubitemid 32662123)
14. Kaas R, Verhoef S, Wesseling J, et al.: Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: Very low risk for subsequent breast cancer. Ann Surg 2010; 251: 488-492.
15. Domchek SM, Friebel TM, Singer CF, et al.: Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010; 304: 967-975.
16. McDonnell SK, Schaid DJ, Myers JL, et al.: Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 2001; 19: 3938-3943. (Pubitemid 32912020)
17. Herrinton LJ, Barlow WE, Yu O, et al.: Efficacy of prophylactic mastectomy in women with unilateral breast cancer: A cancer research network project. J Clin Oncol 2005; 23: 4275-4286. (Pubitemid 46207002)
18. Peralta EA, Ellenhorn JD, Wagman LD, et al.: Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg 2000; 180: 439-445. (Pubitemid 32166835)
19. Lyman GH, Giuliano AE, Somerfield MR, et al.: American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005; 23: 7703-7720. (Pubitemid 46291835)
20. Soran A, Falk J, Bonaventura M, et al.: Is routine sentinel lymph node biopsy indicated in women undergoing contralateral prophylactic mastectomy? Magee-Womens Hospital experience. Ann Surg Oncol 2007; 14: 646-651. (Pubitemid 46175310)
21. Black D, Specht M, Lee JM, et al.: Detecting occult malignancy in prophylactic mastectomy: Preoperative MRI versus sentinel lymph node biopsy. Ann Surg Oncol 2007; 14: 2477-2484. (Pubitemid 47389556)
22. Yi M, Meric-Bernstam F, Middleton LP, et al.: Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer 2009; 115: 962-971.
23. Liberman L, Morris EA, Kim CM, et al.: MR imaging findings in the contralateral breast of women with recently diagnosed breast cancer. AJR Am J Roentgenol 2003; 180: 333-341. (Pubitemid 36135009)